© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 10, 741-749,
May 15, 2002
© 2002 Oxford University Press
ARTICLE |
In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus
Affiliations of authors: A. Hemminki, B. Liu, D. T. Curiel (Division of Human Gene Therapy and Gene Therapy Center, Departments of Medicine, Pathology and Surgery), K. R. Zinn, T. R. Chaudhuri (Department of Radiology), R. A. Desmond (Comprehensive Cancer Center Biostatistics Unit), B. E. Rogers (Department of Radiation Oncology), M. N. Barnes, R. D. Alvarez (Department of Obstetrics and Gynecology), University of Alabama at Birmingham.
Correspondence to: Akseli Hemminki, M.D., Ph.D., Division of Human Gene Therapy, WTI 602, 1824 6th Ave. S., University of Alabama at Birmingham, Birmingham, AL 35294–3300 (e-mail: akseli{at}uab.edu).
Background: Adenovirus-based gene therapy is a promising approach to treat advanced cancers that are resistant to other treatments. However, many primary cells lack the requisite coxsackie-adenovirus receptor (CAR), limiting the in vivo efficacy of gene therapy. Recently, a modified adenovirus that is not dependent on CAR expression for infectivity was developed. We used noninvasive imaging to investigate the in vivo antitumor efficacy of gene therapy using this adenovirus in an animal model of ovarian cancer. Methods: The adenoviral vectors RGDTKSSTR (CAR-independent) and AdTKSSTR (CAR-dependent) express herpes simplex virus thymidine kinase (TK) for molecular chemotherapy and the human somatostatin receptor subtype 2 (SSTR) for noninvasive nuclear imaging. Subcutaneous or peritoneal human xenograft ovarian cancers were established from highly aggressive SKOV3.ip1 cells in immune-deficient mice. Adenoviral constructs were infected intratumorally or intraperitoneally once a day for 3 days. Control mice received three injections, one per day, of Ad5Luc1, a CAR-dependent adenoviral vector that includes a luciferase marker gene. The somatostatin analogue 99mTc-P2045 was used for noninvasive in vivo imaging of RGDTKSSTR that was injected into subcutaneous tumors. For mice with peritoneal tumors, survival was compared among the different treatment groups using Kaplan–Meier analysis with the log-rank statistic. All statistical tests were two-sided. Results: Tumor-associated RGDTKSSTR could be detected 15 days after introduction of the vector. In the subcutaneous model, tumors injected with RGDTKSSTR were statistically significantly smaller than those injected with AdTKSSTR (P<.001). In the intraperitoneal model, mice treated with RGDTKSSTR lived longer (survival at day 45 = 63.6%; 95% confidence interval [CI] = 35.2% to 92.0%) than those treated with AdTKSSTR (survival at day 45 = 0%) or Ad5Luc1 (survival at day 45 = 18.1%; 95% CI = 0.0% to 41.0%). Discussion: RGDTKSSTR shows antitumor efficacy against ovarian cancer in vivo in animal models. The virus can be imaged noninvasively and may have the potential to be a useful agent for treating ovarian cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Matthews, P. E. Noker, B. Tian, S. D. Grimes, R. Fulton, K. Schweikart, R. Harris, R. Aurigemma, M. Wang, M. N. Barnes, et al. Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer Clin. Cancer Res., June 15, 2009; 15(12): 4131 - 4137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Guse, T. Ranki, M. Ala-Opas, P. Bono, M. Sarkioja, M. Rajecki, A. Kanerva, T. Hakkarainen, and A. Hemminki Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses Mol. Cancer Ther., October 1, 2007; 6(10): 2728 - 2736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Belousova, R. Harris, K. Zinn, M. A. Rhodes-Selser, A. Kotov, O. Kotova, M. Wang, R. Aurigemma, Z. B. Zhu, D. T. Curiel, et al. Circumventing Recombination Events Encountered with Production of a Clinical-Grade Adenoviral Vector with a Double-Expression Cassette Mol. Pharmacol., November 1, 2006; 70(5): 1488 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kangasniemi, T. Kiviluoto, A. Kanerva, M. Raki, T. Ranki, M. Sarkioja, H. Wu, F. Marini, K. Hockerstedt, H. Isoniemi, et al. Infectivity-Enhanced Adenoviruses Deliver Efficacy in Clinical Samples and Orthotopic Models of Disseminated Gastric Cancer. Clin. Cancer Res., May 15, 2006; 12(10): 3137 - 3144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Montaner, A. Sodhi, A. K. Ramsdell, D. Martin, J. Hu, E. T. Sawai, and J. S. Gutkind The Kaposi's Sarcoma-Associated Herpesvirus G Protein-Coupled Receptor as a Therapeutic Target for the Treatment of Kaposi's Sarcoma Cancer Res., January 1, 2006; 66(1): 168 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Russell and K.-W. Peng Primer on Medical Genomics Part X: Gene Therapy Mayo Clin. Proc., November 1, 2003; 78(11): 1370 - 1383. [Abstract] [PDF]
|
|
|
|
 |
|
 T. F. Massoud and S. S. Gambhir Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes & Dev., March 1, 2003; 17(5): 545 - 580. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Russell Adenovirus Gene Therapy for Ovarian Cancer J Natl Cancer Inst, May 15, 2002; 94(10): 706 - 707. [Full Text] [PDF]
|
|